NCT07114315RecruitingPhase 2
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
A Phase II Clinical Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer. Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- First submitted
- 3 Aug 2025
- Start date
- 19 Sept 2025
- Primary completion date
- Aug 2027
- Lead sponsor
- Akeso
- Diseases
- Pancreatic cancer
- NCT number
- NCT07114315
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 160
- From 19 Sept 2025 to the primary completion date, Aug 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Except for PDAC, the subjects had other malignant tumors within the 5 years prior to enrollment.
- Prior systemic therapy with either TGF-β inhibitors or anti-angiogenic agents.
- Previous history of myocarditis, cardiomyopathy, and malignant arrhythmia.
Other illness
- There is a history of non infectious pneumonia that requires systemic glucocorticoid treatment.
- History of severe bleeding tendency or coagulation dysfunction.
Other
- There is central nervous system (CNS) metastasis, spinal cord compression, or meningeal metastasis.
- There are pleural effusion, pericardial effusion, or ascites with clinical symptoms or requiring repeated drainage.
- Pregnant or lactating female subject.
Who the study is looking for
- Be able and willing to provide written informed consent.
- Have a life expectancy of at least 3 months.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Subjects with histologically or cytologically confirmed advanced/metastatic pancreatic ductal adenocarcinoma (PDAC), who have progressed on ≤2 prior lines of systemic therapy.
- According to RECIST v1.1, there is at least one measurable lesion.
- Has adequate organ function.
- All subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 90 days after the last dose of study treatment.
- Able to to comply with all requirements of study participation (including all study procedures).
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongshan Hospital Affiliated to Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Tianjin Medical University Cancer Institute and Hospital Coordinator of this site? Confirm its status | Tianjin | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.